nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—SLC6A2—sympathetic nervous system—adrenal gland cancer	0.106	0.197	CbGeAlD
Duloxetine—HTR2A—sympathetic nervous system—adrenal gland cancer	0.0634	0.118	CbGeAlD
Duloxetine—HTR2A—vein—adrenal gland cancer	0.0593	0.111	CbGeAlD
Duloxetine—NPY1R—adrenal cortex—adrenal gland cancer	0.0451	0.0841	CbGeAlD
Duloxetine—CYP1A2—urine—adrenal gland cancer	0.0444	0.0829	CbGeAlD
Duloxetine—NPY1R—Peptide GPCRs—GNRHR—adrenal gland cancer	0.0392	0.0877	CbGpPWpGaD
Duloxetine—NPY1R—gonad—adrenal gland cancer	0.0374	0.0697	CbGeAlD
Duloxetine—NPY1R—pituitary gland—adrenal gland cancer	0.0365	0.068	CbGeAlD
Duloxetine—HTR2A—urine—adrenal gland cancer	0.0348	0.0648	CbGeAlD
Duloxetine—NPY1R—adrenal gland—adrenal gland cancer	0.0326	0.0607	CbGeAlD
Duloxetine—CYP2D6—urine—adrenal gland cancer	0.0317	0.059	CbGeAlD
Duloxetine—NPY1R—Endothelin Pathways—GNAS—adrenal gland cancer	0.0232	0.052	CbGpPWpGaD
Duloxetine—NPY1R—Peptide GPCRs—TSHR—adrenal gland cancer	0.0209	0.0468	CbGpPWpGaD
Duloxetine—HTR6—Serotonin Receptor 4/6/7 and NR3C Signaling—GNAS—adrenal gland cancer	0.0133	0.0298	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—SFPQ—adrenal gland cancer	0.0131	0.0294	CbGpPWpGaD
Duloxetine—SLC6A2—gonad—adrenal gland cancer	0.0127	0.0237	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.0124	0.0277	CbGpPWpGaD
Duloxetine—SLC6A2—adrenal gland—adrenal gland cancer	0.0111	0.0206	CbGeAlD
Duloxetine—CYP2D6—Codeine and Morphine Metabolism—ABCB1—adrenal gland cancer	0.0099	0.0222	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—GNRHR—adrenal gland cancer	0.00941	0.0211	CbGpPWpGaD
Duloxetine—HTR6—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—adrenal gland cancer	0.00885	0.0198	CbGpPWpGaD
Duloxetine—Protriptyline—ABCB1—adrenal gland cancer	0.00814	0.476	CrCbGaD
Duloxetine—HTR2A—GPCRs, Other—GNRHR—adrenal gland cancer	0.00783	0.0175	CbGpPWpGaD
Duloxetine—HTR2A—gonad—adrenal gland cancer	0.00762	0.0142	CbGeAlD
Duloxetine—HTR2A—pituitary gland—adrenal gland cancer	0.00744	0.0139	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.0074	0.0166	CbGpPWpGaD
Duloxetine—HTR2A—adrenal gland—adrenal gland cancer	0.00665	0.0124	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.0066	0.0148	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—GNRH1—adrenal gland cancer	0.00564	0.0126	CbGpPWpGaD
Duloxetine—Fluoxetine—ABCB1—adrenal gland cancer	0.00556	0.325	CrCbGaD
Duloxetine—SLC6A3—Alpha-synuclein signaling—BAD—adrenal gland cancer	0.00532	0.0119	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00532	0.0119	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—KCNJ5—adrenal gland cancer	0.00528	0.0118	CbGpPWpGaD
Duloxetine—HTR6—G alpha (s) signalling events—TSHR—adrenal gland cancer	0.0051	0.0114	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—GNRHR—adrenal gland cancer	0.00507	0.0113	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—TSHR—adrenal gland cancer	0.00502	0.0112	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00483	0.0108	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—GNAS—adrenal gland cancer	0.00483	0.0108	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.00456	0.0102	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GNRHR—adrenal gland cancer	0.00453	0.0101	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—GNRHR—adrenal gland cancer	0.0044	0.00985	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—KCNJ5—adrenal gland cancer	0.00404	0.00905	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GNRHR—adrenal gland cancer	0.00394	0.00881	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—POMC—adrenal gland cancer	0.00385	0.00862	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—GNRHR—adrenal gland cancer	0.00347	0.00777	CbGpPWpGaD
Duloxetine—Propranolol—ABCB1—adrenal gland cancer	0.00339	0.198	CrCbGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.00336	0.00751	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—POMC—adrenal gland cancer	0.00325	0.00727	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—PRKACA—adrenal gland cancer	0.00324	0.00725	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00319	0.00713	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—GNRH1—adrenal gland cancer	0.00304	0.0068	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TOP2A—adrenal gland cancer	0.003	0.00672	CbGpPWpGaD
Duloxetine—HTR6—G alpha (s) signalling events—GNAS—adrenal gland cancer	0.00297	0.00665	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—GNAS—adrenal gland cancer	0.00292	0.00654	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.00291	0.00652	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00289	0.00648	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GNRHR—adrenal gland cancer	0.00285	0.00639	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00284	0.00636	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.00273	0.00611	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—adrenal gland cancer	0.00272	0.00608	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00265	0.00594	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—GNRH1—adrenal gland cancer	0.00264	0.0059	CbGpPWpGaD
Duloxetine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—adrenal gland cancer	0.00263	0.0059	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00258	0.00578	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TSHR—adrenal gland cancer	0.00258	0.00577	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—GNRHR—adrenal gland cancer	0.00256	0.00572	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00249	0.00558	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.00243	0.00545	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—adrenal gland cancer	0.00236	0.00528	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—GNRHR—adrenal gland cancer	0.00222	0.00497	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—GNRH1—adrenal gland cancer	0.00208	0.00465	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—PRKACA—adrenal gland cancer	0.00202	0.00453	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.00201	0.0045	CbGpPWpGaD
Duloxetine—HTR6—G alpha (s) signalling events—POMC—adrenal gland cancer	0.002	0.00448	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—POMC—adrenal gland cancer	0.00197	0.0044	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00196	0.00439	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—PRKACA—adrenal gland cancer	0.00195	0.00436	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—TSHR—adrenal gland cancer	0.00185	0.00415	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PRKACA—adrenal gland cancer	0.00185	0.00414	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.00179	0.00401	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00178	0.00399	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.00175	0.00391	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CDC42—adrenal gland cancer	0.00173	0.00387	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GNRH1—adrenal gland cancer	0.00171	0.00383	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00165	0.0037	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CDC42—adrenal gland cancer	0.00157	0.00351	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SPRY2—adrenal gland cancer	0.00156	0.0035	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.00156	0.00348	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—PRKACA—adrenal gland cancer	0.00155	0.00347	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—GNRH1—adrenal gland cancer	0.00153	0.00343	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TSHR—adrenal gland cancer	0.00152	0.00341	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—GNAS—adrenal gland cancer	0.0015	0.00336	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00144	0.00323	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MEN1—adrenal gland cancer	0.00143	0.00321	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—adrenal gland cancer	0.00138	0.00308	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—TSHR—adrenal gland cancer	0.00136	0.00306	CbGpPWpGaD
Duloxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.00135	0.00303	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—GNRH1—adrenal gland cancer	0.00133	0.00298	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00131	0.00294	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—adrenal gland cancer	0.00126	0.00282	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00125	0.00281	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—TSHR—adrenal gland cancer	0.00119	0.00265	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00118	0.00263	CbGpPWpGaD
Duloxetine—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.00115	0.00257	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00114	0.00255	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—adrenal gland cancer	0.00113	0.00253	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—POMC—adrenal gland cancer	0.00111	0.00249	CbGpPWpGaD
Duloxetine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.0011	0.00246	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PRKACA—adrenal gland cancer	0.00109	0.00245	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—BRAF—adrenal gland cancer	0.00109	0.00244	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—GNAS—adrenal gland cancer	0.00108	0.00241	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00107	0.00239	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—PTGS2—adrenal gland cancer	0.00106	0.00237	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GNRHR—adrenal gland cancer	0.00105	0.00236	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00105	0.00234	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—POMC—adrenal gland cancer	0.00101	0.00226	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000978	0.00219	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.000953	0.00213	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TSHR—adrenal gland cancer	0.000951	0.00213	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	0.000941	0.00211	CbGpPWpGaD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.00093	0.00208	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CDC42—adrenal gland cancer	0.000927	0.00208	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00092	0.00206	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IGF2—adrenal gland cancer	0.000894	0.002	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GNAS—adrenal gland cancer	0.000886	0.00198	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.000865	0.00194	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IGF1R—adrenal gland cancer	0.000864	0.00193	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—BRAF—adrenal gland cancer	0.000835	0.00187	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	0.000833	0.00187	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—adrenal gland cancer	0.000803	0.0018	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—adrenal gland cancer	0.000803	0.0018	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—GNAS—adrenal gland cancer	0.000794	0.00178	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GNRH1—adrenal gland cancer	0.000786	0.00176	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GNRHR—adrenal gland cancer	0.000775	0.00173	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TSHR—adrenal gland cancer	0.000771	0.00173	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	0.000762	0.00171	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CTNNB1—adrenal gland cancer	0.000759	0.0017	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.000751	0.00168	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	0.000748	0.00167	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TERT—adrenal gland cancer	0.000744	0.00167	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—POMC—adrenal gland cancer	0.000726	0.00162	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00072	0.00161	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.000702	0.00157	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TSHR—adrenal gland cancer	0.0007	0.00157	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—GNAS—adrenal gland cancer	0.000689	0.00154	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—adrenal gland cancer	0.000685	0.00153	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000683	0.00153	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GNRH1—adrenal gland cancer	0.000682	0.00153	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000677	0.00152	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	0.000675	0.00151	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNRHR—adrenal gland cancer	0.000673	0.00151	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00067	0.0015	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	0.000663	0.00148	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—BAD—adrenal gland cancer	0.000647	0.00145	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000638	0.00143	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GNRH1—adrenal gland cancer	0.00063	0.00141	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000626	0.0014	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00061	0.00136	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—GNAS—adrenal gland cancer	0.000609	0.00136	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TSHR—adrenal gland cancer	0.000608	0.00136	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—POMC—adrenal gland cancer	0.000597	0.00134	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—BRAF—adrenal gland cancer	0.000589	0.00132	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000588	0.00132	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—POMC—adrenal gland cancer	0.000583	0.00131	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CDC42—adrenal gland cancer	0.000579	0.0013	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SPRY2—adrenal gland cancer	0.000577	0.00129	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—EGFR—adrenal gland cancer	0.000571	0.00128	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TSHR—adrenal gland cancer	0.000562	0.00126	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—GNAS—adrenal gland cancer	0.000553	0.00124	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.000536	0.0012	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—POMC—adrenal gland cancer	0.000535	0.0012	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MEN1—adrenal gland cancer	0.000528	0.00118	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SDHB—adrenal gland cancer	0.000522	0.00117	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000503	0.00113	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—POMC—adrenal gland cancer	0.000494	0.00111	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.000477	0.00107	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CDC42—adrenal gland cancer	0.00047	0.00105	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.000465	0.00104	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GNRH1—adrenal gland cancer	0.000464	0.00104	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—POMC—adrenal gland cancer	0.000464	0.00104	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GNAS—adrenal gland cancer	0.000449	0.001	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SDHB—adrenal gland cancer	0.000442	0.000989	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000436	0.000977	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CDC42—adrenal gland cancer	0.000426	0.000954	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000426	0.000953	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SPRY2—adrenal gland cancer	0.000425	0.00095	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSHR—adrenal gland cancer	0.000414	0.000926	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—POMC—adrenal gland cancer	0.00041	0.000918	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000408	0.000913	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GNAS—adrenal gland cancer	0.000407	0.000912	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PRKACA—adrenal gland cancer	0.000403	0.000903	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNRH1—adrenal gland cancer	0.000403	0.000902	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00039	0.000872	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MEN1—adrenal gland cancer	0.000389	0.000871	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—POMC—adrenal gland cancer	0.000372	0.000834	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CDC42—adrenal gland cancer	0.00037	0.000829	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SPRY2—adrenal gland cancer	0.000369	0.000825	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSHR—adrenal gland cancer	0.000359	0.000804	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GNAS—adrenal gland cancer	0.000354	0.000792	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000348	0.000778	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDC42—adrenal gland cancer	0.000342	0.000766	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MEN1—adrenal gland cancer	0.000338	0.000756	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EGFR—adrenal gland cancer	0.000337	0.000755	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—RRM1—adrenal gland cancer	0.000336	0.000752	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SDHD—adrenal gland cancer	0.000336	0.000752	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF2—adrenal gland cancer	0.00033	0.000738	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GNAS—adrenal gland cancer	0.000327	0.000732	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1R—adrenal gland cancer	0.000319	0.000714	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—POMC—adrenal gland cancer	0.000302	0.000676	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKACA—adrenal gland cancer	0.000297	0.000665	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—RRM1—adrenal gland cancer	0.000285	0.000637	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SDHD—adrenal gland cancer	0.000285	0.000637	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—adrenal gland cancer	0.000283	0.000634	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TERT—adrenal gland cancer	0.000274	0.000614	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—POMC—adrenal gland cancer	0.000274	0.000614	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—POMC—adrenal gland cancer	0.000262	0.000587	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKACA—adrenal gland cancer	0.000258	0.000577	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDC42—adrenal gland cancer	0.000252	0.000564	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MED12—adrenal gland cancer	0.000251	0.000561	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF2—adrenal gland cancer	0.000243	0.000543	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GNAS—adrenal gland cancer	0.000241	0.000539	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BAD—adrenal gland cancer	0.000239	0.000534	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—POMC—adrenal gland cancer	0.000238	0.000533	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1R—adrenal gland cancer	0.000235	0.000525	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—adrenal gland cancer	0.00022	0.000493	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDC42—adrenal gland cancer	0.000219	0.00049	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BRAF—adrenal gland cancer	0.000217	0.000486	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MED12—adrenal gland cancer	0.000212	0.000475	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF2—adrenal gland cancer	0.000211	0.000472	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—adrenal gland cancer	0.000211	0.000471	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNAS—adrenal gland cancer	0.000209	0.000468	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1R—adrenal gland cancer	0.000204	0.000456	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—adrenal gland cancer	0.000202	0.000452	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	0.00019	0.000425	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	0.000183	0.000409	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BAD—adrenal gland cancer	0.000176	0.000393	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—adrenal gland cancer	0.000175	0.000393	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—adrenal gland cancer	0.000162	0.000363	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BRAF—adrenal gland cancer	0.00016	0.000358	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000157	0.000352	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—adrenal gland cancer	0.000155	0.000347	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PRKACA—adrenal gland cancer	0.000155	0.000347	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BAD—adrenal gland cancer	0.000153	0.000342	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	0.000151	0.000339	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNAS—adrenal gland cancer	0.000148	0.000332	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	0.000145	0.000325	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—adrenal gland cancer	0.000141	0.000315	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BRAF—adrenal gland cancer	0.000139	0.000311	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—adrenal gland cancer	0.000135	0.000301	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNAS—adrenal gland cancer	0.000126	0.000281	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—adrenal gland cancer	0.000124	0.000279	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCB1—adrenal gland cancer	0.000123	0.000276	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000116	0.000259	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—adrenal gland cancer	0.000104	0.000234	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNB1—adrenal gland cancer	0.0001	0.000225	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—adrenal gland cancer	9.98e-05	0.000223	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—adrenal gland cancer	9.16e-05	0.000205	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—adrenal gland cancer	8.45e-05	0.000189	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	7.96e-05	0.000178	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—adrenal gland cancer	7.96e-05	0.000178	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—adrenal gland cancer	7.69e-05	0.000172	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—adrenal gland cancer	6.74e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—adrenal gland cancer	6.68e-05	0.00015	CbGpPWpGaD
